Bone Marrow Grafting for Leukemia and Lymphoma
Sponsor
Stanford University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT00186147
Collaborator
National Cancer Institute (NCI) (NIH), National Institutes of Health (NIH) (NIH)
9,999
1
981
10.2
Study Details
Study Description
Brief Summary
The purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The purpose of this study is to acquire critical tissue and biological samples that can be evaluated to elucidate underlying mechanisms of disease control, transplant related complications and overall outcomes
Study Design
Study Type:
Observational
Anticipated Enrollment
:
9999 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Bone Marrow Grafting for Leukemia and Lymphoma
Study Start Date
:
Mar 1, 1988
Anticipated Primary Completion Date
:
Dec 1, 2069
Anticipated Study Completion Date
:
Dec 1, 2069
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Graft recipients and donors
|
Procedure: collection and storage of tissue samples for research
Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
|
Outcome Measures
Primary Outcome Measures
- Identify and characterize proteins and genes that may contribute to the development and progression of cancer. [blood sample is collected prior transplant, periodically during the first three months and then indefinately at follow up]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:- All hematopoietic cell transplant recipients and donors who agree to participate
Exclusion Criteria:- Subject does not agree to participate
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Stanford University School of Medicine | Stanford | California | United States | 94305 |
Sponsors and Collaborators
- Stanford University
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
Investigators
- Principal Investigator: David Miklos, Stanford University
- Principal Investigator: Robert S Negrin, Stanford University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186147
Other Study ID Numbers:
- IRB-08903
- BMT19
First Posted:
Sep 16, 2005
Last Update Posted:
Aug 2, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: